The medical device maker said Q3 revenue is estimated at $448 mil, below the company's previous estimate of $465 mil-$485 mil. Analysts are expecting sales of $477 mil. Edwards Lifesciences (EW) cited austerity measures in Europe as a reason for the decline in sales. The company will release Q3 results Oct. 19. Shares fell 1% to 107.41.